Results 21 to 30 of about 33,645 (162)

Amiodarone Use and All‐Cause Mortality in Patients With a Continuous‐Flow Left Ventricular Assist Device

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2022
Background Atrial and ventricular arrhythmias are commonly encountered in patients with advanced heart failure, with amiodarone being the most commonly used antiarrhythmic drug in continuous‐flow left ventricular assist device (CF‐LVAD) recipients.
Rakesh Gopinathannair, Naga Venkata K. Pothineni, Jaimin R. Trivedi, Henri Roukoz, Jennifer Cowger, Mustafa M. Ahmed, Adarsh Bhan, Ashwin K. Ravichandran, Geetha Bhat, Amin Al Ahmad, Andrea Natale, Luigi Di Biase, Mark S. Slaughter, Dhanunjaya Lakkireddy   +13 more
doaj   +1 more source

Systematic review of the use of intravenous amiodarone and nifekalant for cardiopulmonary resuscitation in Japan

Journal of Arrhythmia, 2014
Background: Intravenous amiodarone is considered to be the first-line drug for the treatment of ventricular tachycardia or fibrillation. However, in Japan, nifekalant had been used before the introduction of amiodarone; therefore, most clinical studies ...
Mari Amino, MD, PhD, Koichiro Yoshioka, MD, PhD, Shigetaka Kanda, MD, Yoshiaki Deguchi, MD, PhD, Mari Nakamura, MD, Yoshinori Kobayashi, MD, PhD, Sadaki Inokuchi, MD, PhD, Teruhisa Tanabe, MD, PhD, Yuji Ikari, MD, PhD   +8 more
doaj   +1 more source

Amiodarone-Induced Acute Liver Injury

Case Reports in Gastroenterology, 2020
Amiodarone is a lipophilic structure with a half-life of 25–100 days. Long-term oral amiodarone is associated with photosensitivity, thyroid dysfunction, and pulmonary and hepatic toxicity.
Rajesh Essrani, Shehriyar Mehershahi, Rajesh Kumar Essrani, Shri Jai Kirshan Ravi, Sajeer Bhura, Anuraj Sudhakaran, Muhammad Hossain, Asif Mehmood   +7 more
doaj   +1 more source

Cardiomyocyte-Targeting Peptide to Deliver Amiodarone

Pharmaceutics, 2023
Background: Amiodarone is underutilized due to significant off-target toxicities. We hypothesized that targeted delivery to the heart would lead to the lowering of the dose by utilizing a cardiomyocyte-targeting peptide (CTP), a cell-penetrating peptide ...
Maliha Zahid, Beth Weber, Ray Yurko, Kazi Islam, Vaishavi Agrawal, Jack Lopuszynski, Hisato Yagi, Guy Salama   +7 more
doaj   +1 more source

NF-κB inhibitor or NAC attenuates amiodarone-induced injury of human lung epithelial cell line BEAS-2B [PDF]

Jichu yixue yu linchuang
Objective To investigate the mechanism of reactive oxygen species (ROS) and pyroptosis in amiodarone-induced lung epithelial cell injury. Methods The viability of cells treated with amiodarone, amiodarone+N-acetylcysteine(ROS inhibitor,NAC) and ...
JI Zezhao, ZHANG Qi, Abuduxukuer·ABULIMITI
doaj   +1 more source

Amiodarone in the aged [PDF]

Australian Prescriber, 2019
Amiodarone is a highly effective antiarrhythmic drug, but can have serious adverse effects, particularly in older patients. If possible it should not be used purely for controlling the heart rate If a prescription for amiodarone is contemplated, particularly for an older patient, consult a cardiologist.
Srinivasan, Meera, Ahmad, Laura, Bhindi, Ravinay, Allahwala, Usaid   +3 more
openaire   +2 more sources

Management of amiodarone-related thyroid problems

Therapeutic Advances in Endocrinology and Metabolism, 2011
Amiodarone is a highly effective and well-established antiarrrhythmic drug. It can be used to treat supraventricular and ventricular tachyarrhythmias and has the added advantage of being well tolerated in patients with impaired left ventricular systolic ...
Shashithej K. Narayana, David R. Woods, Christopher J. Boos   +2 more
doaj   +1 more source

Amiodarone and the thyroid.

Endokrynologia Polska, 2015
Amiodarone, a benzofuranic iodine-rich antiarrhythmic drug, causes thyroid dysfunction in 15-20% of cases. Amiodarone can cause both hypothyroidism (AIH, amiodarone-induced hypothyroidism) and thyrotoxicosis (AIT, amiodarone-induced thyrotoxicosis). AIH is treated by L-thyroxin replacement and does not need amiodarone discontinuation.
Agata Jabrocka-Hybel, Tomasz Marcin Bednarczuk, Bartalena, Luigi, Dorota Pach, Ruchała, Marek, Kamiński, Grzegorz, Marta Kostecka-Matyja, Alicja Hubalewska-Dydejczyk   +7 more
openaire   +3 more sources

Local Use of Hydrogel with Amiodarone in Cardiac Surgery: Experiment and Translation to the Clinic

Gels, 2021
The objective of this study was to study the use of the hydrogel biopolymer based on sodium alginate (“Colegel”) with a drug substance—amiodarone—for the prevention of postoperative atrial fibrillation (POAF) in cardiac surgery.
Vladimir Shvartz, Teymuraz Kanametov, Maria Sokolskaya, Andrey Petrosyan, Tatyana Le, Olga Bockeria, Leo Bockeria   +6 more
doaj   +1 more source

Use of haloperidol in amiodarone induced delirium

Annals of Indian Psychiatry, 2022
Amiodarone, a versatile Class III antiarrhythmic drug, is considered one of the most effective agents in counteracting supraventricular and ventricular tachyarrhythmia.
Rachit Sharma, Ranveer Singh, Markanday Sharma   +2 more
doaj   +1 more source